Latest Middle East News

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.

Fitzroy River Corporation's latest quarterly report reveals a dip in royalty income but highlights progress on major silver and gold projects, alongside strategic moves in energy royalties.

Sprintex has locked in A$30 million in distribution agreements across the UK, Turkiye, and India, while advancing its innovative G25 Jet Blower launch, signaling a strong growth trajectory in energy-efficient technologies.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Icetana Limited has announced a fully underwritten renounceable entitlement offer to raise approximately $2.65 million, aiming to bolster sales, marketing, and product development efforts. The offer, priced at $0.02 per new share, opens on February 3 and closes on February 14, 2025.

Icetana Limited reports a challenging December quarter with declining revenues but secures significant new contracts and launches a fully underwritten $2.65 million rights issue.

Icetana AI has launched a fully underwritten renounceable entitlement offer to raise approximately A$2.65 million, aiming to bolster sales, marketing, and product development. The company is also nearing a potential $1.77 million deal linked to its Baghdad Safe City project in Iraq.